Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APAC in Patients With Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia
NCT07352800Phase 2Recruiting
- Sponsor
- Aplagon
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of APAC in peripheral arterial occlusive disease (PAOD) and chronic limb-threatening ischemia (CLTI) (9 arms), sponsored by Aplagon. Primary endpoint: Treatment-Emergent Adverse Events at Day 90. Started Jan 2026; status: recruiting.
02
Drugs
APAC
03
Conditions
peripheral arterial occlusive disease (PAOD)chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on NCT07352800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07352800.